CDSCO nod to AstraZeneca cancer drug Tremelimumab Ruchika Sharma2 Jun 2023 6:23 AM GMTThe approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials) in...
AstraZeneca announces positive results from ovarian cancer combo therapy trial Ruchika Sharma7 April 2023 6:00 AM GMTThe safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the...
All SAEs including death should be reported: CDSCO Panel tells AstraZeneca about Durvalumab Dr. Divya Colin25 March 2023 12:30 PM GMTNew Delhi: Granting the protocol amendment proposal presented by drug major AstraZeneca for anticancer drug Durvalumab, the Subject Expert Committee...
Imfinzi plus Imjudo approved in EU for patients with advanced liver and non small cell lung cancers: AstraZeneca Ruchika Sharma25 Feb 2023 4:30 AM GMTUK: AstraZeneca has announced that Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations have been approved in the European Union...
AstraZeneca India gets CDSCO nod for Durvalumab to treat biliary tract cancer Ruchika Sharma17 Feb 2023 6:30 AM GMTNew Delhi: Science-led biopharmaceutical company, AstraZeneca India, has announced additional indication approval from Central Drugs...
AstraZeneca gets Japanese approval for Imfinzi, Imjudo to treat 3 types of cancer Ruchika Sharma28 Dec 2022 6:00 AM GMTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Setback to AstraZeneca: Imfinzi fails as monotherapy for non-small lung cancer Ruchika Sharma20 Dec 2022 8:00 AM GMTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca Imfinzi plus chemotherapy recommended for marketing authorisation in EU for advanced biliary tract cancer Ruchika Sharma15 Nov 2022 12:14 PM GMTUK: AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult...
AstraZeneca gets USFDA nod for Imfinzi, Imjudo with chemotherapy to treat metastatic non-small cell lung cancer Ruchika Sharma11 Nov 2022 9:00 AM GMTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca gets USFDA nod for Imfinzi plus chemotherapy to treat advanced biliary tract cancer Ruchika Sharma5 Sep 2022 8:00 AM GMTBiliary tract cancer is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder.
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: study Dr. Shravani Dali7 July 2022 2:30 PM GMTDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, according to a recent study published in the NEJM Evidence Patients...
AstraZeneca gets CDSCO panel nod to study anticancer drug Durvalumab Dr. Divya Colin3 Jun 2022 1:30 PM GMTNew Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
